Concord Biotech's shares surged over 6% after receiving USFDA approval for its Tofacitinib Tablets in 5 mg and 10 mg strengths. This approval for rheumatoid arthritis and other conditions is expected to bolster its U.S. market presence and product portfolio, targeting a $500 million market opportunity.
Concord Biotech's shares surged over 6% after receiving USFDA approval for its Tofacitinib Tablets in 5 mg and 10 mg strengths. This approval for rheumatoid arthritis and other conditions is expected to bolster its U.S. market presence and product portfolio, targeting a $500 million market opportunity.
<iframe src="https://hindustansphere.com/embed/cluster/cd7759bfb9ae955e418a081a2eff44eb527eee68" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Concord Biotech shares gain 6% after USFDA approval for Tofacitinib tablets"></iframe>
